Cooper Companies posts record cash flow and tax benefit

The Cooper Companies Inc reported non-GAAP earnings per share of $1.15 for the third quarter, marking the eleventh consecutive quarter of results above market expectations. The company generated record quarterly free cash flow of $273 million, a figure that highlights its operational efficiency despite mixed revenue trends across its segments.

A key financial driver was the resolution of a tax matter with HMRC, which resulted in a discrete benefit of $307 million. This settlement also secures non-GAAP tax benefits for at least the next decade, reinforcing the firm's projection of $2.2 billion in cumulative free cash flow over fiscal 2026-2028, as noted in coverage by GN markets/earnings (en-US).

Inventory adjustments weigh on vision care

CooperVision revenue remained essentially flat year over year due to a proactive reduction in U.S. channel inventory. Management attributed this to previous buying ahead of price increases and portfolio rationalization of legacy hydrogels, which declined by double digits. These measures are intended to prevent an inventory overhang in the coming year.

The company expects these inventory corrections to continue impacting fourth-quarter results, with CooperVision organic revenue projected to decline between 2% and flat. CEO Al White confirmed that U.S. end-market consumption remains steady in the mid-single digits, indicating that the revenue softness is strictly a supply chain adjustment rather than a demand collapse.

Fertility segment drives organic growth

CooperSurgical delivered solid performance with organic fertility growth of 5%, driven by genomics advancements and new clinic contracts. However, the segment faces competitive pressure in the non-hormonal IUD market, which influenced the valuation during recent strategic reviews. Growth in Asia Pacific remains challenging, with MiSight sales declining in China amid difficult local market conditions.

Forward outlook and tax rate changes

For the fourth quarter, The Cooper Companies guides for total organic growth between 0% and 2%. The company anticipates returning to normal growth rates in fiscal 2027 once inventory rationalization is complete. Management is investing in commercial execution, including sales force expansion and AI-driven tools, to support revenue objectives.

A scheduled increase in GILTI is expected to raise the non-GAAP effective tax rate to roughly 17.5% in fiscal 2027, up from 15.5% this year. This increase reflects broader international tax regulations rather than company-specific operational changes, impacting the net margin profile for the coming fiscal year.